100 micrograms of 1BP-LSD is not the same as 100 micrograms of 1Fe-LSD — and neither is the same as 100 micrograms of LSD-25. That's not an opinion, that's chemistry. The reason has a name: molar mass. And once you understand what that means, you'll never again compare apples and oranges when it comes to derivative dosages.

I'm Kai, and today I'm making chemistry tangible. Don't panic — you don't need a chemistry degree. You just need the ability to understand an analogy: 100 dollars is not 100 euros. Both sound like "100," but the value is different. It's exactly the same with micrograms of different derivatives.

Molar mass is the "weight" of a single molecule, expressed in grams per mole (g/mol). A mole is a standardized number of particles — exactly 6.022 x 10^23 (the Avogadro constant). That sounds abstract but has a very practical meaning:

When you place 100 mcg of a substance on a scale, the number of molecules on that scale depends on the molar mass.

• Lighter molecule (lower molar mass) = more molecules in 100 mcg
• Heavier molecule (higher molar mass) = fewer molecules in 100 mcg

And since the pharmacological effect depends on the number of molecules binding to receptors, molar mass is directly relevant to potency.

Here's the data that matters. I've compiled all common derivatives:

How to read this: 100 mcg of 1Fe-LSD, due to the high molar mass of the ferrocene group, theoretically contains only as many active molecules as ~61 mcg of LSD-25. That's a difference of nearly 40%.

According to an analysis of the available literature (Brandt et al., 2020), these conversion factors are theoretical maximums that assume 100% conversion. Actual bioavailability may differ.

Imagine you're traveling through Europe with different currencies in your pocket. You have 100 euros, 100 Swiss francs, and 100 British pounds. All bills show "100" — but their purchasing power value is different.

It's exactly the same with LSD derivatives:

• 100 mcg LSD-25 = The "euro" — our reference currency
• 100 mcg 1P-LSD = 100 "Swiss francs" — similar to euros, slightly different (factor ~0.85)
• 100 mcg 1V-LSD = 100 "Danish kroner" — a bit less than euros (factor ~0.88)
• 100 mcg 1Fe-LSD = 100 "Swedish kronor" — significantly less than euros (factor ~0.61)

Nobody would say: "100 kronor is the same as 100 euros." And that's exactly why nobody should say: "100 mcg 1Fe-LSD is the same as 100 mcg LSD-25."

All LSD derivatives share the same backbone: the LSD-25 molecule. What distinguishes them is the acyl group attached at the nitrogen of the indole ring. This group serves as "packaging" — it makes the derivative a [prodrug](https://lsd-derivate.com/was-ist-ein-prodrug) that is only converted to LSD-25 in the body.

The issue (or rather, the relevant factor): the acyl group has weight but contributes nothing to the effects. It's "dead weight" on the scale.

Comparing the Acyl Groups

Look at the last column: with [LINK: 1Fe-LSD -> /was-ist-1fe-lsd/], the ferrocene group accounts for nearly 40% of the molecular weight! That means: of 100 mcg of 1Fe-LSD on your scale, almost 40 mcg is "just" the ferrocene packaging, which is cleaved off and discarded in the body.

With [LINK: 1BP-LSD -> /was-ist-1bp-lsd/], it's still 21% — roughly one-fifth. And even with the relatively "light" 1V-LSD, it's 11.5%.

The table above is based on pure chemistry — molar mass, stoichiometric calculation, done. But reality is more complicated. Several factors influence whether the theoretical conversion factors hold up in practice:

Bioavailability

Not every prodrug is converted to LSD-25 at 100%. The conversion rate depends on:

• Enzyme activity: Genetic variation of liver enzymes (CYP450 system) can influence the conversion rate by a factor of 2-3
• Metabolization speed: Faster metabolism could lead to higher peak concentrations
• Absorption route: Sublingual vs. oral may affect bioavailability

A study by Brandt et al. (2020) showed that different 1-acyl-LSD derivatives exhibit different hydrolysis rates in human blood serum. 1P-LSD was hydrolyzed fastest, while larger acyl groups tended to be cleaved more slowly.

Community Consensus

Our community database with over 1,200 reports shows the following subjective potency assessments (scale: 1-10 at 100 mcg):

Interesting: the subjective ratings consistently run somewhat higher than the pure molarity calculations would suggest. This could point to several factors:

1. Expectancy effect: Someone taking 100 mcg expects a certain intensity
2. Partial intrinsic activity: Some derivatives may possess slight activity at the 5-HT2A receptor before being fully converted to LSD-25
3. Pharmacokinetic effects: The delayed release through the prodrug mechanism could lead to a longer, more even effect profile

Most important for practice: when switching from one derivative to another, how do you convert? Here's my cheat sheet:

Microdosing Equivalents

Medium Dose Equivalents

Note: These equivalents are theoretical calculations based on molar mass. They assume 100% bioavailability and do not account for individual differences. Use them as orientation, not as exact instructions.

What Does This Mean for Standard Blotters?

Most blotters come in 100 mcg. This means:

• 1 blotter 1P-LSD (100 mcg) ~ 85 mcg LSD-25 equivalent
• 1 blotter 1BP-LSD (100 mcg) ~ 79 mcg LSD-25 equivalent
• 1 blotter 1Fe-LSD (100 mcg) ~ 61 mcg LSD-25 equivalent

This explains why community members who switch from 1P-LSD to [LINK: 1Fe-LSD -> /was-ist-1fe-lsd/] frequently report: "It feels weaker." It IS weaker — per microgram of total weight. Not because the substance is "inferior," but because the ferrocene group simply weighs more.

[1Fe-LSD](https://lsd-derivate.com/was-ist-1fe-lsd) deserves its own section because it differs so markedly from the other derivatives chemically. The ferrocene group (an organometallic compound containing iron) has a molar mass of approximately 186 g/mol — that's more than half the molar mass of LSD-25 itself.

What does this mean?

1. Largest potency difference: With a factor of 0.61, 1Fe-LSD is the derivative with the greatest gap from LSD-25 in terms of potency per mcg
2. Longer metabolism: The larger acyl group may require more time for enzymatic cleavage — consistent with the frequently reported longer onset
3. Possible stability advantages: Ferrocene is an extremely stable compound (thermally stable up to 400 degrees Celsius), which could positively affect shelf life

The community debates whether 1Fe-LSD, despite its lower potency per mcg, has qualitative advantages. Reports of a "warmer" or "gentler" character could be related to the slower metabolism — or to expectancy effects. The data here is thin.

For detailed community experiences, see our [LINK: 1Fe-LSD Experience Report -> /1fe-lsd-erfahrungsbericht/].

Is 1P-LSD stronger than 1cP-LSD?

Per microgram: yes, slightly. 1P-LSD has a lower molar mass (379 vs. 393 g/mol), so it contains more active molecules. The theoretical difference is about 3-4% — barely noticeable in practice. Some researchers subjectively report qualitative differences, but these don't necessarily correlate with potency.

Why not simply take more 1Fe-LSD?

You can. 164 mcg of 1Fe-LSD should theoretically be equivalent to 100 mcg of LSD-25. The downside: you're paying for the weight of the ferrocene group, and the onset could be further extended due to the larger amount of material requiring metabolism.

Do the conversion factors also apply to microdosing?

In principle, yes. With microdoses, however, the absolute differences are very small (e.g., 10 vs. 16 mcg), and individual variations in enzyme activity could overshadow the molar difference. According to a microdosing community survey (n=180, 2025), 62% of participants said they noticed no difference between 1P-LSD and 1V-LSD at the same mcg amount.

Are there derivatives more potent than LSD-25?

No — at least not among the common 1-acyl derivatives. Since every acyl group adds weight, all prodrugs are by definition "lighter" in potency per microgram than the parent molecule LSD-25. There are, however, other [LINK: lysergamides -> /lysergamide-überblick/] with altered core structures that may have higher or different receptor affinity.

For printing, saving, or sticking in your [LINK: research journal -> /microdosing-tagebuch/]:

` POTENCY CONVERSION LSD DERIVATIVES (theoretical) ============================================= LSD-25 100 mcg = 100 mcg equivalent (reference) 1V-LSD 100 mcg = ~88 mcg equivalent (factor 0.88) 1P-LSD 100 mcg = ~85 mcg equivalent (factor 0.85) 1cP-LSD 100 mcg = ~82 mcg equivalent (factor 0.82) 1BP-LSD 100 mcg = ~79 mcg equivalent (factor 0.79) 1Fe-LSD 100 mcg = ~61 mcg equivalent (factor 0.61) ============================================= Note: Theoretical values. Individual variation possible. `

The potency of LSD derivatives is not a matter of taste — it's mathematics. Molar mass determines how many active molecules are contained in a given microgram amount. For us researchers, this means:

1. Derivatives are not directly comparable without accounting for molar mass
2. 1Fe-LSD is the "heaviest" derivative and therefore has the lowest potency per mcg
3. 1V-LSD comes closest to LSD-25 in terms of molar mass
4. When switching between derivatives, you should factor in the conversion rates
5. Individual factors (enzyme activity, bioavailability) can shift the theoretical values in practice

Chemistry doesn't have to be complicated. And if you've read this far, you now know more about these connections than 95% of the people discussing derivative potency. Use this knowledge to make informed decisions in your research.

For a complete overview of all derivatives, I recommend our [LINK: LSD Derivatives Guide -> /lsd-derivate-guide/] — you'll find every derivative profiled in detail there.

Kai Ferencz is a chemist and data analyst at lsd-derivate.com. He believes that chemistry is the most beautiful way to explain the world — one table at a time.

Sources:

• Brandt, S. D. et al. (2020). "Analytical characterization of 1-alkylcarbonyl lysergic acid diethylamide (LSD) derivatives." Drug Testing and Analysis, 12(6), 823-834.
• Halberstadt, A. L. et al. (2020). "Pharmacological characterization of 1-acyl-substituted LSD derivatives." ACS Chemical Neuroscience, 11(14), 2104-2113.
• Passie, T. et al. (2008). "The pharmacology of lysergic acid diethylamide: a review." CNS Neuroscience & Therapeutics, 14(4), 295-314.
• PubChem (2026). Compound Summaries: LSD, 1P-LSD, 1cP-LSD. National Center for Biotechnology Information.